检索结果-南通市图书馆

Alterations of Lymphoid Enhancer Factor-1 Isoform Expression in Solid Tumors and Acute Leukemias

Acta Biochimica et Biophysica Sinica 2005年第3期37卷 173-180页

作者： Wenbing WANG Ping JI Bjrn STEFFEN Ralf METZGER Paul M.SCHNEIdER Hartmut HALFTER Mark SCHRAdER Wolfgang E.BERdEL Hubert SERVE Carsten MLLER-TIdOW Institute of Life Sciences,Jiangsu university,Zhenjiang 212013.China hematology and oncology.and neurology,department of medicine,university of mnster,d-48129 mnster,germany dematology of Visceral and Vascular Surgery,university of Cologne,d-50931 Cologne,germany department of Urolooy,Free university Berlin,d-12200 Berlin. InstituteofLifeSciences JiangsuUniversityZhenjiang212013China

Two major transcripts of lymphoid enhancer factor-1(LEF-1)have been *** longisoform with β-catenin binding domain functions as a transcriptional enhancer *** short isoformderives from an intronic promoter and exhibits dominant negative ***,alterations of LEF-1isoforms distribution have been described in colon *** the current study we employed a quantitativereal-time reverse transcription PCR method(TaqMan)to analyze expression of LEF-1 isoforms in a largecohort of human tumor(n=304)and tumor-free control samples(n=56).The highest expression level ofLEF-1 was found in carcinoma samples whereas brain cancer samples expressed *** of LEF-1 was different in distinct cancer *** example,the mRNA level of LEF-1 was lower in testiculartumor samples compared with tumor-free control *** epithelial cancers,significant LEF-1expression was also found in hematopoietic *** hematological malignancies,overall LEF-1 level washigher in lymphocytic leukemias compared with myeloid leukemias and normal ***,acute myeloid leukemia and acute lymphocytic leukemia showed a significantly increased fraction of theoncogenic LEF-1 compared with chronic lymphocytic leukemia and chromc myeloid *** together,these data suggest that LEF-1 is abundantly expressed in human tumors and the ratio of the oncogenic andthe dominant negative short isoform altered not only in carcinomas but also in leukemia.

关键词： AML β-catenin isoform lymphoid enhancer factor(LEF-1) solid tumor

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

引用

Chinese Journal of Cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song dan Jiang Lingling Yu Yixuan Chen daobin Zhou Yue Li depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) division of Therapeutic drug Monitoring of Chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of Chinese Society of Clinical oncology(CSCO) Expert Committee on Leukemia of Chinese Society of Clinical oncology(CSCO) Society of Integrative Cardio-oncology of China Anti-Cancer Association(CACA) Chinese Society of hematology of Chinese Medical Association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits medicine Exchange Association(SMEA) department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China department of hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China department of hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China department of hematology and oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China department of hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,development,and Evaluation(GRAdE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

LIGHT sensitizes IFNγ-mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondria pathways

引用

Cell Research 2004年第2期14卷 117-124页

作者： Man Chao ZHANG~*, Hong Peng LIU, Lisa L dEMCHIK, Yi Fan ZHAI, da Jun YANG division of hematology/oncology, department of Internal medicine, the university of Michigan, Ann Arbor, MI 48109-0934, USA. division of hematology/oncology Department of Internal Medicine the University of Michigan Ann Arbor MI 48109-0934 USA

LIGHT [homologous to lymphotoxins, shows inducible expression, and competes with herpes simplex virus glycoprotein d for herpes virus entry mediator (HVEM/TR2)] is a new member of TNF superfamily. The HT-29 colon cancer cell line is the most sensitive to LIGHT-induced, IFNγ-mediated apoptosis among the cell lines we have examined so far. Besides downregulation of Bcl-XL, upregulation of Bak, and activation of both PARP [poly (AdP-ribose) polymerase] and dFF45 (dNA fragmentation factor), LIGHT-induced, IFNγ-mediated apoptosis of HT-29 cells involves extensive caspase activation. Caspase-8 and caspase-9 activation, as shown by their cleavages appeared as early as 24 h after treatment, whereas caspase-3 and caspase-7 activation, as shown by their cleavages occurred after 72 h of LIGHT treatment. Caspase-3 inhibitor Z-dEVd-FMK (benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone) and a broad range caspase inhibitor Z-VAd-FMK (benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone) were able to block LIGHT-ind

关键词： HT-29 LIGHT apoptosis Bcl-X_L caspase.

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

中国成人急性淋巴细胞白血病诊断与治疗指南(2024年版)

引用

中华血液学杂志 2024年第5期45卷 417-429页

作者：中国抗癌协会血液肿瘤专业委员会中华医学会血液学分会白血病淋巴瘤学组王建祥秘营昌王迎不详中国医学科学院血液病医院(中国医学科学院血液学研究所) 天津300020 中国医学科学院血液病医院

成人急性淋巴细胞白血病(ALL)是成人最常见的急性白血病之一, 目前国际上有比较统一的诊断标准和不同研究组报道的系统治疗方案。我国自2013年至今发表了三版中国成人ALL诊断与治疗的专家共识/指南, 对该病种诊断治疗水平提升有重要意义... 详细信息

成人急性淋巴细胞白血病(ALL)是成人最常见的急性白血病之一, 目前国际上有比较统一的诊断标准和不同研究组报道的系统治疗方案。我国自2013年至今发表了三版中国成人ALL诊断与治疗的专家共识/指南, 对该病种诊断治疗水平提升有重要意义。2022年WHO造血与淋巴组织肿瘤分类对ALL(前体淋巴细胞肿瘤——淋巴母细胞白血病/淋巴瘤)的分类进行了更新, 提出了一些新概念;近年来免疫治疗快速发展, 在一定程度上提高了成人ALL的疗效, 且抗体、嵌合抗原受体T细胞(CAR-T细胞)产品陆续在国内上市, 临床实践日益丰富。为促进成人ALL临床诊疗的规范, 本指南参考国内外最新指南和文献, 荟萃国内外最新研究成果, 为成人ALL的诊断、治疗、疗效监测提供参考意见。

关键词：白血病,淋巴细胞,急性成人诊断治疗疗效监测

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The path toward prognostication and prediction in stage Ⅱ colon cancer

引用

Engineering Sciences 2014年第4期12卷 51-58页

作者： Mohindra Nisha division of hematology/oncology Department of Medicine Feinberg School of Medicine Northwestern University Chicago Illinois 60611 USA Robert H Lurie Comprehensive Cancer Center Northwestern University Chicago Illinois 60611 USA

Currently,there are several newer biomarkers that may be clinically useful in colon cancer. This paper focuses on a few of these biomarkers,namely microsatellite instability,loss of heterozygosity at chromosome 18q(LOH18q) and multi-gene assays,and discusses the clinical evidence behind their predictive or prognostic abilities. The results show that although there have been several newer prognostic factors identified,such as LOH18 q and multi-gene assays,none of these factors can predict benefit from treatment. Therefore,ongoing prospective clinical trials are still needed to further assess the role and optimal use of these tests.

关键词： colon cancer stage Ⅱ stage Ⅲ microsatellite instability LOH18q multi-gene

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

高危多发性骨髓瘤诊断与治疗中国专家共识(2024年版)

引用

中华血液学杂志 2024年第5期45卷 430-435页

作者：中国抗癌协会血液肿瘤专业委员会骨髓瘤与浆细胞疾病学组中国临床肿瘤学会多发性骨髓瘤专家委员会邱录贵马军安刚傅琤琤不详中国医学科学院血液病医院(中国医学科学院血液学研究所) 血液与健康全国重点实验室国家血液系统疾病临床医学研究中心细胞生态海河实验室天津300020 哈尔滨血液病肿瘤研究所哈尔滨150010 中国医学科学院血液病医院苏州大学附属第一医院

高危多发性骨髓瘤(High risk multiple myeloma,HRMM)是指在当前规范诊疗下,总生存期不足2~3年的骨髓瘤患者。结合多种静态和动态预后因素进行危险度分层,早期识别HRMM患者,并采用个体化风险分层治疗策略,有望显著改善HRMM患者不良生存... 详细信息

高危多发性骨髓瘤(High risk multiple myeloma,HRMM)是指在当前规范诊疗下,总生存期不足2~3年的骨髓瘤患者。结合多种静态和动态预后因素进行危险度分层,早期识别HRMM患者,并采用个体化风险分层治疗策略,有望显著改善HRMM患者不良生存结局。尽管近年来,国内对HRMM的临床价值已达成共识,但在HRMM的定义、高危因素、危险度分层和治疗等方面仍存在混乱和不明确之处,亟需规范。为提高中国医师对HRMM的诊治水平,中国抗癌协会血液肿瘤专业委员会和中国临床肿瘤学会多发性骨髓瘤专家委员会组织相关专家制定了本共识。该共识旨在明确HRMM的定义、高危因素和危险度分层体系,提供HRMM的治疗推荐,从而提高中国HRMM患者的生存质量和预后。

关键词：多发性骨髓瘤高危诊断治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

恶性肿瘤中医维持治疗专家共识

引用

北京中医药大学学报 2024年第1期47卷 141-148页

作者：中华中医药学会血液病分会中国民族医药学会血液病分会中国中西医结合学会肿瘤专业委员会北京中西医结合学会肿瘤专业委员会中华中医药学会血液病创新研究与转化平台侯丽董青李潇吕丽媛翟苗杰陈信义不详北京中医药大学东直门医院

早在2006年,世界卫生组织已将恶性肿瘤定义为慢性疾病,维持治疗是其特定治疗阶段的重要施治策略。众所周知,维持治疗在恶性血液系统疾病如急性白血病的治疗中发挥着重要作用。近年来,维持治疗已在多种实体瘤,如晚期非小细胞肺癌[1]、结... 详细信息

早在2006年,世界卫生组织已将恶性肿瘤定义为慢性疾病,维持治疗是其特定治疗阶段的重要施治策略。众所周知,维持治疗在恶性血液系统疾病如急性白血病的治疗中发挥着重要作用。近年来,维持治疗已在多种实体瘤,如晚期非小细胞肺癌[1]、结直肠癌[2]、乳腺癌[3]等疾病中陆续得到临床应用,并证明通过维持治疗可明显延长患者生存时间,提高生活质量。有鉴于此,2017年,中国抗癌协会乳腺癌专业委员会发布《中国晚期乳腺癌维持治疗专家共识》[4]。

关键词：恶性肿瘤中医维持治疗专家共识

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Expression of hepatitis B virus surface antigen in 120 Hodgkin's lymphoma patients

引用

Chinese Journal of Cancer 2010年第8期29卷 735-740页

作者： Miao-Zhen Qiu1,2, dan-Yun Ruan1,2, Zhi-Qiang Wang1,2, Hui-Yan Luo1,2, Kai-Yuan Teng1,2, Zhong-Jun Xia1,3, Yue Lu1,3, Hui-Qiang Huang1,2, Wen-Qi Jiang1,2, Rui-Hua Xu1,2 1 State Key Laboratory of oncology in South China, Sun Yat-sen university Cancer Center, Guangzhou, Guangdong 510060, P. R. China 2 department of Medical oncology, Sun Yat-sen university Cancer Center, Guangzhou, Guangdong 510060, P. R. China 3 department of hematology oncology, Sun Yat-sen university Cancer Center, Guangzhou, Guangdong 510060, P. R. China Sun Yat-sen university Cancer Center State Key Laboratory of Oncology in South China Guangdong Guangzhou 510060

Background and Objective: Little is known about the incidence of hepatitis B virus (HBV) infection in Hodgkin's lymphoma patients. This study was to evaluate the impact of HBV infection on the survival of Hodgkin's lymphoma patient. Methods: Clinical data of 120 Hodgkin's lymphoma patients treated at the Sun Yat-sen university Cancer Center between January 2004 and October 2007 were collected. The impact of prognostic factors including HBV infection on survival was examined by univariate and multivariate analyses. A log-rank test was used for univariate analysis and the Cox proportional hazards regression model was used for multivariate analysis. Results: Of the 120 patients, 18 (15.0%) were hepatitis B virus surface antigen (HBsAg)-positive. The HBsAg-positive patients had lower 5-year survival rate than did the HBsAg-negative ones (66.9% vs. 91.3%, P = 0.006). When the patients were divided into early-stage (Ⅰ+Ⅱ) and advanced-stage (Ⅲ+Ⅳ) groups, the 5-year survival rate was significantly different between the HBsAg-positive and -negative patients in early-stage group (64.8% vs. 96.0%, P different in advanced-stage group (75.0% vs. 84.8%, P=0.667). Both univariate and multivariate analyses showed that radiotherapy and HBV infection were independent prognosis factors for the patients with early-stage Hodgkin's lymphoma (P=0.006 and 0.014, respectively). Conclusions: The incidence of HBV infection is similar between Hodgkin's lymphoma patients and normal population. HBV infection is an independent prognosis factor for survival in the patients with early-stage Hodgkin's lymphoma.

关键词：乙肝病毒表面抗原淋巴瘤患者乙肝表面抗原多因素分析金病毒感染肝炎病毒

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

KLF4 expression is associated with differentiation stages of leukemia cells in both cell lines and patients

KLF4 expression is associated with differentiation stages of...

引用

中华医学会第十七次全国儿科学术大会

作者： Xiaoping Gao,Yongmin Tang division of hematology-oncology,Children’s Hospital of Zhejiang university School of medicine

Objectives:Biomarkers on malignant cells may predict prognostic ***(u|¨)ppel-like factor 4(KLF4) has been reported to be expressed variably on leukemia cells,but its expression patterns in leukemias with different di...

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

儿童急性髓系白血病诊疗专家共识(2024)

引用

中华儿科杂志 2024年第10期62卷 909-919页

作者：中国医师协会儿科医师分会儿童血液肿瘤学组中华医学会儿科学分会血液学组中华医学会儿科学分会肿瘤学组中华儿科杂志编辑委员会郑胡镛李静王天有不详首都医科大学附属北京儿童医院国家儿童医学中心首都医科大学附属北京儿童医院血液病中心北京100045

急性髓系白血病(AML)占儿童急性白血病的15%~20%,生存率仅为60%~70%,其诊治具有一定挑战性。近20年来,国内尚无针对儿童AML诊疗建议的更新,且成人AML诊疗指南不完全适用于儿童AML。根据国际上AML领域的研究进展,结合儿童AML特点及我国儿... 详细信息

急性髓系白血病(AML)占儿童急性白血病的15%~20%,生存率仅为60%~70%,其诊治具有一定挑战性。近20年来,国内尚无针对儿童AML诊疗建议的更新,且成人AML诊疗指南不完全适用于儿童AML。根据国际上AML领域的研究进展,结合儿童AML特点及我国儿童AML多中心研究结果,中国医师协会儿科医师分会儿童血液肿瘤学组、中华医学会儿科学分会血液学组、中华医学会儿科学分会肿瘤学组组织制定本共识,旨在为中国儿童AML的临床诊断和治疗提供决策依据,指导临床实践及研究工作。

关键词：急性髓系白血病中华医学会中国医师协会儿童急性白血病儿科医师肿瘤学儿科学分会多中心研究

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：